Basal Insulin is the Most Widely Used Insulin in Diabetic Patients Owing to its Long-Acting Effect

Diabetes is a type of a metabolic disorder characterized by a high blood sugar level over a prolonged period. Symptoms often include frequent urination, increased thirst, and increased appetite.The main job of basal insulin is to keep one's blood glucose levels stable during periods of fasting, like while sleeping. During fasting, the liver continuously secretes glucose into the bloodstream. Basal insulin helps maintain these glucose levels. Without basal insulin, glucose levels would rise at an alarming rate. It ensures that one's cells are fed with a constant glucose stream to burn for energy throughout the day.

Type (Lantus, Levemir, Toujeo, Others)

Application (Type I Diabetes, Type II Diabetes, Gestational Diabetes, Prediabetes)

𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 𝐭𝐨 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅:- https://www.theinsightpartners.com/sample/TIPRE00019744/?utm_source=OpenPR&utm_medium=10209

The basal insulin market has shown a significant evolution over the forecast period. The rise of the basal insulin market is driven by therising prevalence of diabetes, the growing geriatric population, technological advancements in insulin delivery devices, and increasing population exposure to risk factors leading to diabetes. Approximately 100 million individuals worldwide need insulin, including all individuals living with type 1 diabetes and 10-25% of individuals with type 2 diabetes. Basal insulin is the most widely used insulin in diabetic patients owing to its long-acting effect. However, although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today are still unable to afford and access it, which is likely to restrict the market's growth. Conversely, product launches are boosting the market's growth. For instance, Tresiba, launched by Novo Nordisk in 2016, received encouraging feedback from the patients and is expected to show tremendous growth during the forecast period (2019-2024) due to its ultra-long-acting effect.

The report also offers key players' profiles in the basal insulin market and their SWOT analysis and market strategies. The report also focuses on the key market players with information on company profiles, financial information of the last three years, components, and services provided, critical development in the past five years.

Top Key Players:-

Novo Nordisk

Sanofi

Eli Lilly and Company.

Biocon.

Julphar

BoehringerIngelheim.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Company

Pfizer

GlaxoSmithKline plc. and Others

Contact US
Contact Person : Ankit Mathur
Phone : +1-646-491-9876
E-mail : sales@theinsightpartners.com

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.